デフォルト表紙
市場調査レポート
商品コード
1719285

レベチラセタム市場- 世界の産業規模、シェア、動向、機会、予測、販売チャネル別（直接販売、間接販売）、最終用途別（てんかん、てんかん重積状態、補助療法、その他）、地域別、競合別、2020-2030年

Levetiracetam Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel (Direct, Indirect), By End Use (Epilepsy, Status Epilepticus, Adjunctive Therapy, Others), By Region and Competition, 2020-2030F

出版日
ページ情報
英文 185 Pages
納期
2～3営業日
カスタマイズ可能
レベチラセタム市場- 世界の産業規模、シェア、動向、機会、予測、販売チャネル別（直接販売、間接販売）、最終用途別（てんかん、てんかん重積状態、補助療法、その他）、地域別、競合別、2020-2030年
出版日: 2025年04月30日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2～3営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

レベチラセタムの世界市場は、2024年に15億9,144万米ドルと評価され、2030年には31億3,883万米ドルに達すると予測され、予測期間中のCAGRは10.48%で成長すると予測されています。

第2世代の抗てんかん薬（AED）であるレベチラセタムは、良好な薬物動態特性、最小限の薬物相互作用、さまざまな発作タイプに対する有効性で高く評価され、医療専門家の間で信頼されています。世界で約5,000万人が罹患しているてんかんの世界の罹患率の上昇が、需要を牽引する大きな要因となっています。さらに、てんかん以外の疾患（神経因性疼痛や不安など）の治療におけるレベチラセタムの役割の拡大により、その用途が広がっています。徐放性製剤や静脈内投与製剤の革新により、患者の服薬アドヒアランスと治療成績が向上し続けています。ドラッグデリバリーの最適化と副作用の最小化を目指した継続的な研究開発により、レベチラセタムは市場の勢いを維持する態勢を整えています。

市場概要
予測期間 2026-2030
市場規模：2024年 15億9,144万米ドル
市場規模：2030年 31億3,883万米ドル
CAGR：2025年～2030年 10.48%
急成長セグメント ダイレクト
最大市場 北米

市場促進要因

ヘルスケア産業の成長

主な市場課題

新興国市場における価格侵食

主要市場動向

神経疾患の有病率の上昇

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界のレベチラセタム市場に与える影響

第5章 世界のレベチラセタム市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 販売チャネル別（直接、間接）
    • 用途別（てんかん、てんかん重積状態、補助療法、その他）
    • 地域別
    • 企業別（2024）
  • 市場マップ

第6章 北米のレベチラセタム市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第7章 欧州のレベチラセタム市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域のレベチラセタム市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第9章 南米のレベチラセタム市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカのレベチラセタム市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収
  • 製品上市
  • 最近の動向

第13章 世界のレベチラセタム市場：SWOT分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 競合情勢

  • Devi Chemscience Private Limited
  • Medikament Pharma
  • HINDUSTAN SILICHEM PRIVATE LIMITED
  • Venkata Narayana Active Ingredients Private Limited
  • Andhra Medi Pharma india Pvt. Ltd.
  • Bhavani Interchem Pvt Ltd
  • Honour Lab Limited
  • Ramis Laboratories Private Limited
  • Lupin Limited
  • Hetero Labs Limited

第16章 戦略的提言

第17章 調査会社について・免責事項

目次
Product Code: 28579

The Global Levetiracetam Market was valued at USD 1,591.44 Million in 2024 and is projected to reach USD 3,138.83 Million by 2030, growing at a CAGR of 10.48% during the forecast period. Levetiracetam, a second-generation antiepileptic drug (AED), is highly regarded for its favorable pharmacokinetic attributes, minimal drug interactions, and effectiveness across various seizure types, making it a trusted option among medical professionals. The rising global incidence of epilepsy, which impacts around 50 million individuals worldwide, is a major factor driving demand. Additionally, levetiracetam's expanding role in treating conditions beyond epilepsy-such as neuropathic pain and anxiety-has broadened its application. Innovations in extended-release and intravenous formulations continue to improve patient adherence and therapeutic outcomes. With ongoing R&D aimed at optimizing drug delivery and minimizing side effects, levetiracetam is poised to maintain strong market momentum.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1,591.44 Million
Market Size 2030USD 3,138.83 Million
CAGR 2025-203010.48%
Fastest Growing SegmentDirect
Largest MarketNorth America

Key Market Drivers

Growth in Healthcare Industry

The robust expansion of the global healthcare sector, driven by increased access to care, rising investment, and technological advancements, is a key growth driver for the levetiracetam market. In developed nations, healthcare spending accounts for a significant share of GDP, such as the USD 4.3 trillion spent in the U.S. in 2021. As the demand for effective neurological treatments grows-especially for chronic conditions like epilepsy-levetiracetam continues to gain prominence for its efficacy and well-tolerated profile. Epilepsy, a noncommunicable neurological condition affecting approximately 50 million people globally, remains prevalent across all age groups. Nearly 80% of those affected live in low- and middle-income regions, where expanding healthcare access is increasing the reach of antiepileptic medications. With early diagnosis and proper treatment, up to 70% of epilepsy patients can achieve seizure control, further bolstering the need for reliable drugs such as levetiracetam in emerging markets.

Key Market Challenges

Price Erosion in Developing Markets

Price erosion due to the proliferation of generic alternatives is a significant challenge impacting the global levetiracetam market, especially in developing regions. Following the expiry of patents for branded versions like Keppra, numerous generic formulations have entered the market, intensifying competition and driving prices downward. In cost-sensitive areas such as Asia, Latin America, and parts of Africa, healthcare systems often prioritize affordability, pushing manufacturers toward low-cost options. While this enhances treatment accessibility, it exerts pressure on profit margins for pharmaceutical companies, particularly those with higher production and regulatory compliance costs. For multinational firms, maintaining brand loyalty and perceived quality becomes increasingly difficult in markets where pricing dictates purchasing decisions.

Key Market Trends

Rising Prevalence of Neurological Disorders

The global rise in neurological disorders is significantly influencing demand for antiepileptic drugs like levetiracetam. Neurological conditions now affect over 3 billion people-approximately 43% of the global population-with common contributors including stroke, dementia, and epilepsy. The growing burden of these disorders across both developed and developing nations is spurring increased pharmaceutical activity. Levetiracetam, due to its broad-spectrum efficacy and favorable safety profile, is increasingly adopted as a primary treatment for various seizure types. Additionally, aging populations, improved diagnostics, and lifestyle factors are driving the prevalence of neurological illnesses. As a result, levetiracetam continues to gain traction as a versatile and dependable therapeutic option in neurology.

Key Market Players

  • Devi Chemscience Private Limited
  • Medikament Pharma
  • HINDUSTAN SILICHEM PRIVATE LIMITED
  • Venkata Narayana Active Ingredients Private Limited
  • Andhra Medi Pharma India Pvt. Ltd.
  • Bhavani Interchem Pvt Ltd
  • Honour Lab Limited
  • Ramis Laboratories Private Limited
  • Lupin Limited
  • Hetero Labs Limited

Report Scope

In this report, the Global Levetiracetam Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Levetiracetam Market, By Sales Channel:

  • Direct
  • Indirect

Levetiracetam Market, By End Use:

  • Epilepsy
  • Status Epilepticus
  • Adjunctive Therapy
  • Others

Levetiracetam Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Levetiracetam Market.

Available Customizations

Global Levetiracetam Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Levetiracetam Market

5. Global Levetiracetam Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Epilepsy, Status Epilepticus, Adjunctive Therapy, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Levetiracetam Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Levetiracetam Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Mexico Levetiracetam Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Canada Levetiracetam Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Levetiracetam Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Levetiracetam Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. Germany Levetiracetam Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Levetiracetam Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Levetiracetam Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Levetiracetam Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Levetiracetam Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Levetiracetam Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Levetiracetam Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. South Korea Levetiracetam Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. Japan Levetiracetam Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Levetiracetam Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. South America Levetiracetam Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Levetiracetam Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Levetiracetam Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Levetiracetam Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Levetiracetam Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Levetiracetam Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Levetiracetam Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Levetiracetam Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Levetiracetam Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Devi Chemscience Private Limited
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Medikament Pharma
  • 15.3. HINDUSTAN SILICHEM PRIVATE LIMITED
  • 15.4. Venkata Narayana Active Ingredients Private Limited
  • 15.5. Andhra Medi Pharma india Pvt. Ltd.
  • 15.6. Bhavani Interchem Pvt Ltd
  • 15.7. Honour Lab Limited
  • 15.8. Ramis Laboratories Private Limited
  • 15.9. Lupin Limited
  • 15.10. Hetero Labs Limited

16. Strategic Recommendations

17. About Us & Disclaimer